Parathyroid hormone analogues in the treatment of osteoporosis (Q37900475)

25 August 2017

1 reference

title

Parathyroid hormone analogues in the treatment of osteoporosis (English)

1 reference

25 August 2017

0 references

Marius E Kraenzlin

1

1 reference

PubMed ID

21750510

25 August 2017

Christian Meier

series ordinal

2

1 reference

25 August 2017

12 July 2011

1 reference

Nature Reviews Endocrinology

25 August 2017

1 reference

25 August 2017

7

1 reference

25 August 2017

647-656

1 reference

25 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2011.108

25 August 2017

0 references

cites work

Pathogenesis of osteoporosis: concepts, conflicts, and prospects

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Mechanisms of anabolic therapies for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The cell biology of parathyroid hormone in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

STUDIES OF CALCIUM AND PHOSPHORUS METABOLISM : V. A STUDY OF THE BONE TRABECULAE AS A READILY AVAILABLE RESERVE SUPPLY OF CALCIUM

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Parathyroid hormone activates PKC-delta and regulates osteoblastic differentiation via a PLC-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Harnessing the parathyroids to create stronger bones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Cellular mechanisms of bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Osteoclast-derived activity in the coupling of bone formation to resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Mechanisms involved in skeletal anabolic therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Clinical update on teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The anabolic effects of parathyroid hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

PTH analogues and osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Reduced risk of back pain following teriparatide treatment: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Recombinant full-length parathyroid hormone (1-84).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

PTH-analogs: comparable or different?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Daily and cyclic parathyroid hormone in women receiving alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effects of teriparatide retreatment in osteoporotic men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Safety of parathyroid hormone for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Of mice and men: divergent risks of teriparatide-induced osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Parathyroid hormone-dependent signaling pathways regulating genes in bone cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Osteosarcoma and teriparatide?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.108

Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis

31 March 2020

1 reference

12 December 2020

Priliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis

1 reference

12 December 2020

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

1 reference

12 December 2020

New anabolic therapies in osteoporosis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2011.108

1 reference

25 August 2017

1 reference

PubMed ID

21750510